Note: This article does not constitute any investment opinions or recommendations; please refer to official/company announcements for accuracy. This article only provides an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.
On the evening of December 8, 2025,SANEGENEBIO, a clinical-stage biotechnology company focused on the development of innovative RNAi therapies,Announced the completion of over $110 million in Series B financing。This round of fundraising will be used to leverage the company's globally leading RNAi drug discovery platform — including the LEAD™ (Ligand and Enhancer Assisted Delivery) extrahepatic delivery platform — to advance clinical-stage pipelines into registrational studies and accelerate the development of multiple pipelines across therapeutic areas.Series B financing was led by a well-known industry institution, with participation from an international sovereign fund, China Biologic Products Group, Legend Capital, Vivo Capital, Invus, SymBiosis, Suzhou Venture Capital, Zhenmai Investment, and Lake Bleu Capital. Strategic investment was also provided by Eli Lilly and Company. Existing shareholders, including Gaoling Ventures, Qiming Venture Partners, K2VC, TF Capital, Oriza Holdings, and Northern Light Venture Capital, continued their support.Since its establishment in 2021, SANEGENEBIO has been committed to developing first-in-class/best-in-class RNAi therapies targeting the liver and extrahepatic tissues based on its proprietary RNAi drug discovery platform. Leveraging this platform, the company has built a diversified pipeline covering different therapeutic areas such as autoimmune diseases, cardiovascular diseases, metabolic disorders, and obesity, with multiple candidates already entering clinical stages. The successful completion of this Series B financing will strongly advance the clinical development and global expansion of the company’s ongoing and planned pipelines, further supporting SANEGENEBIO in achieving continuous breakthroughs in the RNAi field.
Dr. Weimin Wang, founder of SANEGENEBIO, stated: "The completion of Series B financing is an important milestone in the company's development process. We are honored to have received support from several global top-tier investment institutions, which not only reflects trust and recognition of the company’s R&D capabilities and corporate vision but also injects key resources for our long-term growth. SANEGENEBIO is always committed to expanding the application boundaries of RNAi technology through continuous innovation, thereby addressing unmet clinical needs worldwide. In the future, the company will fully advance the global late-stage clinical development of its drug candidates while leveraging the LEAD™ platform to push more transformative candidate drugs into the clinical stage."SANEGENEBIO is a globally integrated clinical-stage biotechnology company focusing on the development of RNAi therapies. Relying on its proprietary GalNAc liver delivery platform and the industry-leading LEAD™ (Ligand and Enhancer Assisted Delivery) extrahepatic delivery platform, the company is committed to addressing significant unmet clinical needs in the fields of obesity, cardiometabolic diseases, and immune-mediated disorders.Founded in 2021 and led by a pioneering team with deep expertise in the RNAi field, SANEGENEBIO has research and development centers in Suzhou, Shanghai, China, and Boston, USA, and has received support from well-known venture capital firms. The LEAD™ platform efficiently delivers siRNA specifically to extrahepatic tissues such as fat, muscle, immune cells, and the central nervous system, achieving efficient, safe, and long-lasting silencing of disease-causing genes while significantly reducing the frequency of dosing.SANEGENEBIO has established a rapidly growing pipeline of research products, currently featuring four clinical-stage drug candidates (one in Phase II and three in Phase I) along with multiple preclinical projects.The company upholds a clear vision: to develop innovative therapies with "Best-In-Class" and "First-In-Class" potential, driving RNAi therapies to become the clinical standard treatment across a broad range of disease areas, and bringing a new generation of transformative treatment options to patients worldwide.Source: SANEGENEBIO
Mastering CAR-T Therapy, Stem Cell Therapy, and Gene
Therapy,Comprehensive Information on Oncolytic Viruses and Nucleic Acid Drugs
